Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Merck Licenses Foundational CRISPR Integration Technology to Promega 2019-12-19 21:00
Asieris Wins Questex's Fierce Innovation Awards - Life Sciences Edition 2019 2019-12-19 13:51
MoA Technology implements CDD Vault to manage its crop protection research data 2019-12-17 17:00
CMT's Manufacturing Automation Asia Summit draws Automotive, Aerospace, Pharma, Electronics, Chemical Manufacturers to Singapore 2019-12-17 09:00
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma 2019-12-17 07:47
etectRx Announces U.S. FDA Clearance of Novel Ingestible Event Marker 2019-12-16 07:06
Drug Manufacturers Eye Analytical Instrumentation to Reduce Operating Costs 2019-12-12 23:11
HemoCue AB, the Pioneer and Global leader in Hemoglobin (Hb) Point-of-care Testing (POCT) to Further Strengthen National Activities in the Combat against Anemia in India 2019-12-12 16:11
Human Microbiome Market to Reach $6.08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics 2019-12-11 23:55
GemVax announced phase II results of GV1001 for Alzheimer's disease treatment at CTAD 2019 2019-12-11 18:40
Xinhua Silk Road: E. China Nanjing Jiangbei New Area aims to develop life and health industry 2019-12-11 16:52
CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST 2019-12-11 11:00
AGC Biologics Expands Plasmid DNA Offering 2019-12-11 09:06
Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma 2019-12-11 08:41
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting 2019-12-10 16:00
CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma 2019-12-10 11:38
Townsville Hospital Treats First Australian Patient With Elekta Unity MR-Linac, a Transformative Approach to Precision Radiation Therapy 2019-12-10 08:13
CStone appoints seasoned pharmaceutical executive Shirley Zhao as the General Manager for Greater China and Head of Commercial 2019-12-06 18:53
Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-LAG-3 Monoclonal Antibody in China 2019-12-06 08:00
Suvoda Secures $40M Investment from LLR Partners 2019-12-05 17:00
1 184 185 186 187 188 247